Clinical Trials Directory
We are doing this study to find out if an experimental drug called AbbV-383 (the study drug) is safe and effective for patients with relapsed/refractory multiple myeloma.
We are doing this study to find out if an experimental drug called upadacitinib (the study drug) is a safe and effective option for people with moderate to severe hidradenitis suppurativa (HS) who did not get adequate relief from standard treatment.
We are doing this study to find out if an experimental drug called ABBV-453 (the study drug) is a safe and effective option for patients with chronic lymphocytic lymphoma (CLL) or small lymphocytic lymphoma (SLL).
We are doing this study to learn more about the sounds coming from a Doppler device when testing arteries. The recording will be used to train a computer program to compare the sounds from healthy arteries to non-healthy arteries.
We are doing this study to find out if an experimental drug called MGD024 (the study drug) is a safe and effective option for patients with different cancers of the blood or bone marrow that have relapsed or do not respond to standard therapy. We will test how the study drug works at different doses during this study in order to find the most effective dose.
A registry is a database of information (data) about patients living with a specific condition. Scientists study the information in the registry to increase what we know about the condition so we can develop better treatments in the future. We have created this registry to collect and store medical data, blood and urine samples from people with an autoimmune disease or rheumatic conditions during pregnancy for possible use in future research.
We are doing this study to learn more about ATTR and its different variants and how they can can be better diagnosed, managed, and treated.
We are doing this study to find out if an experimental drug called NTLA-2001 (the study drug) is a safe and effective option for people with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study drug is made using the CRISPR-CaS9 gene editing system. The intent of the study drug that is being tested is to target the TTR gene and make it inactive.